MX392259B - ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a - Google Patents

ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a

Info

Publication number
MX392259B
MX392259B MX2019014294A MX2019014294A MX392259B MX 392259 B MX392259 B MX 392259B MX 2019014294 A MX2019014294 A MX 2019014294A MX 2019014294 A MX2019014294 A MX 2019014294A MX 392259 B MX392259 B MX 392259B
Authority
MX
Mexico
Prior art keywords
inhibitors
fused
rings
modulators
receptor
Prior art date
Application number
MX2019014294A
Other languages
English (en)
Inventor
Christopher W Lange
Hiroko Tanaka
Penglie Zhang
Pingchen Fan
Rajinder Singh
Rebecca M Lui
Sreenivas Punna
Venkat Reddy Mali
Viengkham Malathong
Yibin Zeng
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX392259B publication Critical patent/MX392259B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)

Abstract

La presente exposición proporciona, inter alia, los Compuestos de Fórmula (I) (ver fórmula I) o sales farmacéuticamente aceptables de los mismos que son moduladores del receptor C5a. También se proporcionan composiciones farmacéuticas y métodos de uso que incluyen el tratamiento de enfermedades o trastornos que implican la activación patológica de C5a y aplicaciones no farmacéuticas.
MX2019014294A 2017-05-31 2018-05-29 ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a MX392259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513010P 2017-05-31 2017-05-31
PCT/US2018/034905 WO2018222598A1 (en) 2017-05-31 2018-05-29 6-5 FUSED RINGS AS C5a INHIBITORS

Publications (1)

Publication Number Publication Date
MX392259B true MX392259B (es) 2025-03-24

Family

ID=64456009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014294A MX392259B (es) 2017-05-31 2018-05-29 ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a

Country Status (13)

Country Link
US (3) US10562896B2 (es)
EP (1) EP3630775B1 (es)
JP (1) JP7141130B2 (es)
KR (1) KR102638253B1 (es)
CN (1) CN110997674B (es)
AR (1) AR111983A1 (es)
AU (1) AU2018277520B2 (es)
IL (1) IL270828B2 (es)
MA (1) MA48803A (es)
MX (1) MX392259B (es)
TW (1) TWI781177B (es)
WO (1) WO2018222598A1 (es)
ZA (1) ZA201907746B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2934507T3 (es) 2017-05-31 2023-02-22 Chemocentryx Inc Anillos fusionados en 5-5 como inhibidores de C5a
JP7141130B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
SG11202009588PA (en) * 2018-04-02 2020-10-29 Chemocentryx Inc PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022093971A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
GB8613591D0 (en) 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
ATE404553T1 (de) 2000-09-29 2008-08-15 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
US7902179B2 (en) * 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487798A4 (en) 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as C5A receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
AU2003265395A1 (en) * 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
WO2007019083A1 (en) 2005-08-04 2007-02-15 Janssen Pharmaceutica N.V. Pyrimidine compounds as serotonin receptor modulators
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
CN102264227B (zh) 2008-12-22 2014-07-23 凯莫森特里克斯股份有限公司 C5aR拮抗剂
KR20120092096A (ko) 2009-09-02 2012-08-20 머크 샤프 앤드 돔 코포레이션 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-ｉｖ 억제제로서의 아미노테트라히드로피란
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
KR20150042271A (ko) 2012-08-16 2015-04-20 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸
CN103421006B (zh) * 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
JP7141130B2 (ja) * 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
ES2934507T3 (es) * 2017-05-31 2023-02-22 Chemocentryx Inc Anillos fusionados en 5-5 como inhibidores de C5a
US10589871B2 (en) 2017-09-25 2020-03-17 Hamilton Sundstrand Corporation Prognostic health monitoring and jam detection for use with an aircraft
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
SG11202009588PA (en) 2018-04-02 2020-10-29 Chemocentryx Inc PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Also Published As

Publication number Publication date
EP3630775B1 (en) 2022-12-14
IL270828B2 (en) 2023-04-01
US11773091B2 (en) 2023-10-03
US20200347049A1 (en) 2020-11-05
AU2018277520B2 (en) 2022-03-17
TW201902895A (zh) 2019-01-16
MA48803A (fr) 2020-04-08
BR112019025049A2 (pt) 2020-06-16
RU2019142942A3 (es) 2021-09-03
EP3630775A1 (en) 2020-04-08
US10562896B2 (en) 2020-02-18
US11384079B2 (en) 2022-07-12
AR111983A1 (es) 2019-09-11
US20180370967A1 (en) 2018-12-27
WO2018222598A1 (en) 2018-12-06
IL270828B (en) 2022-12-01
US20230151002A1 (en) 2023-05-18
KR20200015604A (ko) 2020-02-12
TWI781177B (zh) 2022-10-21
CN110997674B (zh) 2022-12-20
ZA201907746B (en) 2023-10-25
CA3064017A1 (en) 2018-12-06
IL270828A (en) 2020-01-30
JP2020522484A (ja) 2020-07-30
KR102638253B1 (ko) 2024-02-16
EP3630775A4 (en) 2020-10-07
RU2019142942A (ru) 2021-06-30
JP7141130B2 (ja) 2022-09-22
CN110997674A (zh) 2020-04-10
AU2018277520A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MX392259B (es) ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
MX383124B (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.
MX391221B (es) Compuestos y composiciones y usos de los mismos.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
EA202090414A1 (ru) Соединения и их применение
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
MX381129B (es) Inhibidores de dopamina-b-hidroxilasa.
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
JOP20200104B1 (ar) مركبات مثبطة لـ btk
EA201992051A1 (ru) Агонисты фарнезоидного x-рецептора и их применение
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.